Sign in

Data breach at Dr Reddy’s forces lab to temporarily shot operations across globe

Updated on: Oct 22, 2020, 15:48:36 IST
Hindustan Times, New Delhi | By
Share
Share via
  • facebook
  • twitter
  • linkedin
  • whatsapp
Copy link
  • copy link
Dr Reddy’s Laboratories had recently received approval from the drugs controller general of India to conduct an adaptive phase 2/3 clinical trial in India for Russia’s Sputnik V vaccine candidate against Coronavirus disease (Covid-19). (REUTERS File)
Dr Reddy’s Laboratories had recently received approval from the drugs controller general of India to conduct an adaptive phase 2/3 clinical trial in India for Russia’s Sputnik V vaccine candidate against Coronavirus disease (Covid-19). (REUTERS File)

The Hyderabad-based lab is authorised to test and distribute the Russian Covid-19 vaccine in India

After reports of a data leak from Hyderabad-based global pharmaceutical company Dr Reddy’s Laboratories Ltd, one of country’s leading pathology laboratory chains came out, IT has been forced to temporarily shut operations in its plants across the world.

Apart from its plant in India, the other plants that have shut include the ones at Brazil, Russia, the United Kingdom and the United States. The breach is reported to have taken place early (India time) Thursday.

Dr Reddy’s Laboratories had recently received approval from the drugs controller general of India to conduct an adaptive phase 2/3 clinical trial in India for Russia’s Sputnik V vaccine candidate against Coronavirus disease (Covid-19).

Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, last month announced that it had inked a deal with India’s Dr Reddy’s for the trial and distribution of their vaccine candidate in India.

Upon regulatory approvals in India, RDIF shall supply 100 million doses of the vaccine to Dr Reddy’s.

According to RDIF, deliveries could potentially begin in late 2020, subject to the completion of successful trials and registration of the vaccine by regulatory authorities in India.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia.

The company is reviewing what led to the data breach.

Mukesh Rathi, CIO, Dr. Reddy’s issued a statement in the matter as reported by the website moneycontrol.com.

“In the wake of a detected cyber-attack, we have isolated all data centre services to take required preventive actions. We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident.”

The shares of Dr Reddy’s declined by nearly 3% following the report of data breach.

  • Rhythma Kaul
    ABOUT THE AUTHOR
    Rhythma Kaul

    Rhythma Kaul is the national health editor of the Hindustan Times. She has been reporting on public health, medicine, and medical research, with a particular focus on how government decisions and health system reforms shape people’s lives. Rhythma has over 25 years of journalistic experience. She joined Hindustan Times in 2008, and has since covered everything from pandemics and infectious diseases to cutting‑edge medical research and climate‑related health challenges. Her stories routinely track the work of the Ministry of Health and Family Welfare, department of pharmaceuticals, and key national health programmes, making complex medical science and policy accessible to a wide audience. One of her prominent news breaks has been the 2012 Baby Falak case: A two-year-old brutally battered baby girl was admitted to AIIMS-Delhi with severe head injuries, multiple fractures, human bite marks, and burns. The police investigation revealed this to be a case of multi-state human-trafficking racket. She was profiled by The Wall Street Journal for breaking this story. Rhythma holds a Master’s degree from Jawaharlal Nehru University, Delhi. Prior to Hindustan Times, she worked with the India Today Group. Rhythma can be contacted at rhythma.kaul@hindustantimes.com. Her X handle is @RamblingBrook.Read More